Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 108 - Dermatologic and Ophthalmic Drugs Advisory Committee - Authorized by Law


Committee NameDermatologic and Ophthalmic Drugs Advisory CommitteeAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number108
Original Establishment Date11/28/1990Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*10
Current Charter Date10/7/2022Designated Fed Officer Position Title*DFO
Date Of Renewal Charter10/7/2024Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*LaToya
Exempt From Renewal*NoDesignated Federal Officer Middle NameA.
Specific Termination AuthorityDesignated Federal Officer Last Name*Bonner
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPharm.D.
Specific Establishment Authority*21 U.S.C. 394Designated Federal Officer Phone*(301) 796-9001
Effective Date Of Authority*11/28/1990Designated Federal Officer Fax*301-847-8533
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*Scientific Technical Program Advisory Board


Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in the treatment of dermatologic and ophthalmic disorders. The Committee answers questions that are designed to help the Agency's efforts in completing its review and to reach a final decisions on new drug applications.
How is membership balanced?*Members are experts in clinical dermatology, dermatopathology, internal medicine, immunology, ophthalmology, and biostatistics. The Committee includes one technically qualified voting member who is identified with consumer interests. The Committee may include one non-voting member who is identified with industry interests.
How frequent & relevant are cmte mtgs?*The Committee did not meet during FY-22. It is expected that the Committee will meet 1-2 times during FY-23.
Why advice can't be obtained elsewhere?*Members of the Committee are drawn from academia, research and/or clinical practice. Their advice and input lends credibility to FDA regulatory decisions. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientists on a full time basis at maximum rates of compensation.
Why close or partially close meetings?The Committee held no closed meetings during FY-22.
Recommendation RemarksThere were no reports required for this Committee in FY-22.

Although this Committee did not meet in FY-22, considerable time was devoted to appointing members, maintaining associated records for these activities, and streamlining paper processes within FDA. In addition, time was spent in the routine care and maintenance of the Committee: the development of a financial report for this website; updating the roster and number of vacancies on our website; completing the annual ethics report; reviewing financial disclosures of current members and providing ethics training. Since the Committee did not meet, no reporting was required.

Although the current charter states that the Committee shall hold meetings approximately 1-2 times a year, this is only an estimation based on data from previous years. As the FDA convenes advisory committees regarding based on the needs of the Agency, it should not be construed as an exact figure.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesYes
Outcome Major Policy ChangesYesAction Issued New RegulationsYes
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionYesAction CommentFDA approves or chooses not to approve an investigational new medical product.
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentN/ANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThe utilization of the Dermatologic and Ophthalmic Drugs Advisory Committee enabled the Agency to obtain required and frequently scarce professional services from the medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the Committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.Grants Review CommentN/A
Number Of Recommendations*29Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe Committee made 29 recommendations from FY-03 through FY-22.Access Agency WebsiteYes
% of Recs Fully Implemented*84.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice. This number represents an approximation of the percentage of recommendations that the agency has fully implemented or plans to fully implement.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe function of an advisory Committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*When appropriate, information is made available to the public. Actions related to guidance documents or other general matters or issues are available publicly when implemented. See Committee website for specific accomplishments: Description*FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Dermatologic and Ophthalmic Drugs Advisory Committee supports FDA's strategic priorities by reviewing and evaluating available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of dermatologic and ophthalmic disorders and makes appropriate recommendations to the Commissioner of Food and Drugs. This supports the development of safe and effective new medical technologies, and advances the status of the Agency as a science-based and science-led regulatory agency, providing global leadership in the protection of public health.
Hide Section - COSTS


Payments to Non-Federal Members*$0.00Est Payments to Non-Fed Members Next FY*$14,134.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$180,533.00Estimated Payments to Federal Staff*$174,066.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$15,679.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$45,133.00Est. Other Costs Next FY*$54,489.00
Total Costs$225,666.00Est. Total Next FY*$258,368.00
Date Cost Last Modified10/8/2022 11:26 AMEst. Fed Staff Support Next FY*1.10
Federal Staff Support (FTE)*1.10Est Cost Remarks
Cost Remarks  
Hide Section - Interest Areas

Interest Areas

Food and Drugs
Food and Drugs
Health Care


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-040366Dermatologic and Ophthalmic Drugs Advisory Committee2021
 COM-038644Dermatologic and Ophthalmic Drugs Advisory Committee2020
 COM-036515Dermatologic and Ophthalmic Drugs Advisory Committee2019
 COM-034723Dermatologic and Ophthalmic Drugs Advisory Committee2018
 COM-001971Dermatologic and Ophthalmic Drugs Advisory Committee2017
 COM-002283Dermatologic and Ophthalmic Drugs Advisory Committee2016
 COM-003740Dermatologic and Ophthalmic Drugs Advisory Committee2015
 COM-004403Dermatologic and Ophthalmic Drugs Advisory Committee2014
 COM-006137Dermatologic and Ophthalmic Drugs Advisory Committee2013
 COM-006652Dermatologic and Ophthalmic Drugs Advisory Committee2012
 COM-008271Dermatologic and Ophthalmic Drugs Advisory Committee2011
 COM-008870Dermatologic and Ophthalmic Drugs Advisory Committee2010
 COM-010428Dermatologic and Ophthalmic Drugs Advisory Committee2009
 COM-010794Dermatologic and Ophthalmic Drugs Advisory Committee2008
 COM-011968Dermatologic and Ophthalmic Drugs Advisory Committee2007
 COM-012648Dermatologic and Ophthalmic Drugs Advisory Committee2006
 COM-013953Dermatologic and Ophthalmic Drugs Advisory Committee2005
 COM-014744Dermatologic and Ophthalmic Drugs Advisory Committee2004
 COM-015684Dermatologic and Ophthalmic Drugs Advisory Committee2003
 COM-016776Dermatologic and Ophthalmic Drugs Advisory Committee2002
 COM-017919Dermatologic and Ophthalmic Drugs Advisory Committee2001
 COM-018592Dermatologic and Ophthalmic Drugs Advisory Committee2000
 COM-019556Dermatologic and Ophthalmic Drugs Advisory Committee1999
 COM-020671Dermatologic and Ophthalmic Drugs Advisory Committee1998
 COM-021700Dermatologic and Ophthalmic Drugs Advisory Committee1997